Abstract
Major depressive disorder (MDD) is a prevalent mental illness associated with significant impairment in quality of life and treatment resistance in as many as 50% of patients. Few alternatives to psychopharmacological and electroconvulsive therapy (ECT) exist. Transcranial magnetic stimulation (TMS) is one such alternative with demonstrated efficacy in the treatment of both MDD and treatment- resistant depression (TRD). Accrued evidence from meta-analyses suggests that rTMS has moderate effect sizes in both MDD and TRD, comparable, though less robust, to those seen in ECT treated patients, and similar to those seen with antidepressant treatment in TRD. To date, rTMS has been used in adult, pediatric, and geriatric populations with success. Predictors of response include lower age, lower degrees of treatment resistance, and the absence of comorbid anxiety or psychotic symptoms. rTMS is cost-effective when compared to existing treatments for TRD including psychopharmacological interventions and ECT. More research, however, is needed to determine the most optimal stimulation parameters. Accelerated treatment over a short duration of time, sequential bilateral stimulation, extended number of pulses per session are potential methods of optimizing efficacy over current unilateral stimulation protocols. The extent to which rTMS can be pushed to engender the greatest possible clinical effects while avoiding seizure induction remains unknown.
Keywords: Transcranial magnetic stimulation, treatment resistant depression, brain stimulation, cost-effectiveness, Major depressive disorder (MDD), electroconvulsive therapy (ECT), comorbid anxiety, psychotic symptoms, clinical effects, seizure induction
Current Pharmaceutical Design
Title:The Role of Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Review
Volume: 18 Issue: 36
Author(s): Jonathan C. Lee, Daniel M. Blumberger, Paul B. Fitzgerald, Zafiris J. Daskalakis and Andrea J. Levinson
Affiliation:
Keywords: Transcranial magnetic stimulation, treatment resistant depression, brain stimulation, cost-effectiveness, Major depressive disorder (MDD), electroconvulsive therapy (ECT), comorbid anxiety, psychotic symptoms, clinical effects, seizure induction
Abstract: Major depressive disorder (MDD) is a prevalent mental illness associated with significant impairment in quality of life and treatment resistance in as many as 50% of patients. Few alternatives to psychopharmacological and electroconvulsive therapy (ECT) exist. Transcranial magnetic stimulation (TMS) is one such alternative with demonstrated efficacy in the treatment of both MDD and treatment- resistant depression (TRD). Accrued evidence from meta-analyses suggests that rTMS has moderate effect sizes in both MDD and TRD, comparable, though less robust, to those seen in ECT treated patients, and similar to those seen with antidepressant treatment in TRD. To date, rTMS has been used in adult, pediatric, and geriatric populations with success. Predictors of response include lower age, lower degrees of treatment resistance, and the absence of comorbid anxiety or psychotic symptoms. rTMS is cost-effective when compared to existing treatments for TRD including psychopharmacological interventions and ECT. More research, however, is needed to determine the most optimal stimulation parameters. Accelerated treatment over a short duration of time, sequential bilateral stimulation, extended number of pulses per session are potential methods of optimizing efficacy over current unilateral stimulation protocols. The extent to which rTMS can be pushed to engender the greatest possible clinical effects while avoiding seizure induction remains unknown.
Export Options
About this article
Cite this article as:
C. Lee Jonathan, M. Blumberger Daniel, B. Fitzgerald Paul, J. Daskalakis Zafiris and J. Levinson Andrea, The Role of Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Review, Current Pharmaceutical Design 2012; 18 (36) . https://dx.doi.org/10.2174/138161212803523644
DOI https://dx.doi.org/10.2174/138161212803523644 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Withdrawal Notice: Clinical Pathways Optimization from Decision Rules Based on Fusion Stream Mining and Fuzzy Unordered Rule Induction Strategy in Diabetes Treatment
Current Bioinformatics Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia
Current Drug Targets Metal Complexes of Biologically Active Ligands as Potential Antioxidants
Current Medicinal Chemistry Obesity- An Adverse Factor in Reproductive Age
Applied Clinical Research, Clinical Trials and Regulatory Affairs Growth Hormone and Insulin-Like Growth Factor-I as an Endocrine Axis in Alzheimers Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Moxifloxacin-induced Hypoglycemia in a Non-diabetic Patient
Current Drug Safety Therapeutic Interventions to Renin-Angiotensin-Aldosterone System, and Vascular Redox State
Recent Patents on Cardiovascular Drug Discovery Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials
Current Diabetes Reviews Cardioprotective Effects of Sour Cherry Seed Extract (SCSE) on the Hypercholesterolemic Rabbit Heart
Current Pharmaceutical Design A Review on Designing Poly (Lactic-co-glycolic Acid) Nanoparticles as Drug Delivery Systems
Pharmaceutical Nanotechnology Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Current Pharmaceutical Design Live Yeast Cell Derivative Induces c-fos Expression in THP-1 Monocytes
Medicinal Chemistry Antidiabetic Effect of Aqueous Corrigiola telephiifolia in Streptozotocin- Induced Diabetic Rats
The Natural Products Journal The Metabolic Syndrome and the Relevance of Nutrients for its Onset
Recent Patents on Biotechnology The Pleiotropic Effects of PPARs on Vascular Cells and Angiogenesis: Implications for Tissue Engineering
Current Stem Cell Research & Therapy Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Development and Clinical use of Prasugrel and Ticagrelor
Current Pharmaceutical Design Seeds of Mung Bean (<i>Vigna radiata</i> (L.) R.Wilczek): Taxonomy, Phytochemistry, Medicinal Uses and Pharmacology
Current Bioactive Compounds